Drug Trial Radar · NCT00951496
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,560
Actual
Start
Aug 11, 2009
Primary completion
Jan 11, 2016
Study completion Jan 11, 2016
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Aug 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies bevacizumab and intravenous (given into a vein) chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving bevacizumab together with intravenous chemotherapy is more effective than giving bevacizumab together with intraperitoneal chemotherapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Conditions
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Malignant Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Primary Peritoneal Clear Cell Adenocarcinoma
- Primary Peritoneal Endometrioid Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Primary Peritoneal Transitional Cell Carcinoma
- Primary Peritoneal Undifferentiated Carcinoma
- Stage II Fallopian Tube Cancer AJCC v6 and v7
- Stage II Ovarian Cancer AJCC v6 and v7
- Stage IIA Fallopian Tube Cancer AJCC v6 and v7
- Stage IIA Ovarian Cancer AJCC V6 and v7
- Stage IIB Fallopian Tube Cancer AJCC v6 and v7
- Stage IIB Ovarian Cancer AJCC v6 and v7
- Stage IIC Fallopian Tube Cancer AJCC v6 and v7
- Stage IIC Ovarian Cancer AJCC v6 and v7
- Stage III Ovarian Cancer AJCC v6 and v7
- Stage III Primary Peritoneal Cancer AJCC v7
- Stage IIIA Ovarian Cancer AJCC v6 and v7
- Stage IIIA Primary Peritoneal Cancer AJCC v7
- Stage IIIB Ovarian Cancer AJCC v6 and v7
- Stage IIIB Primary Peritoneal Cancer AJCC v7
- Stage IIIC Ovarian Cancer AJCC v6 and v7
- Stage IIIC Primary Peritoneal Cancer AJCC v7
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
BevacizumabBiological
Given IV
CarboplatinDrug
Given IV
CarboplatinDrug
Given IP
CisplatinDrug
Given IP
Laboratory Biomarker AnalysisOther
Correlative studies
PaclitaxelDrug
Given IV
PaclitaxelDrug
Given IP
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Progression-free SurvivalTime frame: Progression-free survival is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.
Locations
503 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
PCR Oncology
Arroyo Grande, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
John Muir Medical Center-Concord Campus
Concord, California
City of Hope Comprehensive Cancer Center
Duarte, California
Marin General Hospital
Greenbrae, California
Long Beach Memorial Medical Center-Todd Cancer Institute
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Saint Joseph Hospital - Orange
Orange, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Sutter Roseville Medical Center
Roseville, California
Sutter Medical Center Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
University of California San Diego
San Diego, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
UCSF Medical Center-Mount Zion
San Francisco, California
Sutter Solano Medical Center/Cancer Center
Vallejo, California
John Muir Medical Center-Walnut Creek
Walnut Creek, California
Colorado Gynecologic Oncology Group
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
University of Colorado
Denver, Colorado
Rocky Mountain Gynecologic Oncology PC
Englewood, Colorado
Danbury Hospital
Danbury, Connecticut
Hartford Hospital
Hartford, Connecticut
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut
The Hospital of Central Connecticut
New Britain, Connecticut
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut
Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut
Showing 40 of 503 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.